Search results
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 6 days agoThe current standard of care in the first line is a combination of Genentech’s Herceptin...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 1 day agoGets Under Your Skin Halozyme Therapeutics is an expert in drug delivery. The company is known for...
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
Zacks via Yahoo Finance· 5 days agoIn 2024, Teva expects Uzedy sales of approximately $80 million. Teva markets biosimilar versions of...
ASCO24: Can Ambrx’s novel ADC break into the metastatic breast cancer market?
Pharmaceutical Technology via Yahoo Finance· 5 days agoThis randomised trial, conducted across 85 centres in China, compared Ambrx Biopharma’s antibody-...
Astra's Enhertu breast cancer trial shows 'unprecedented' results
Reuters via Yahoo News· 7 days agoThe findings, presented in Chicago at the annual meeting of the American Society of Clinical...
UCLA oncologist Dr. Dennis Slamon awarded Szent-Gy | Newswise
Newswise· 4 days agoDr. Dennis Slamon, a world-renowned oncologist and scientist whose groundbreaking research has...
The Zacks Analyst Blog Highlights Roche, Wells Fargo, General Aerospace and Key Tronic
Zacks via Yahoo Finance· 4 days agoThe outlook for 2024 is ordinary as well. Competition from biosimilars for established cancer...
... Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07...
Benzinga· 7 days agoEvorpacept in combination with PADCEV®, an approved antibody-drug conjugate ("ADC"), demonstrated promising activity and was generally well toleratedCompany to host conference call and webcast with Samuel A. Funt,